Unlocking liver health: Can tackling myosteatosis spark remission in metabolic dysfunction‐associated steatotic liver disease?

Author:

Henin Guillaume12ORCID,Loumaye Audrey3,Deldicque Louise4,Leclercq Isabelle A.2,Lanthier Nicolas12

Affiliation:

1. Service d'Hépato‐Gastroentérologie Cliniques universitaires Saint‐Luc, UCLouvain Brussels Belgium

2. Laboratory of Hepatogastroenterology, Institut de Recherche Expérimentale et Clinique Université catholique de Louvain (UCLouvain) Brussels Belgium

3. Service d'Endocrinologie, Diabétologie et Nutrition Cliniques universitaires Saint‐Luc, UCLouvain Brussels Belgium

4. Institute of Neuroscience UCLouvain Louvain‐la‐Neuve Belgium

Abstract

AbstractMyosteatosis is highly prevalent in metabolic dysfunction‐associated steatotic liver disease (MASLD) and could reciprocally impact liver function. Decreasing muscle fat could be indirectly hepatoprotective in MASLD. We conducted a review to identify interventions reducing myosteatosis and their impact on liver function. Non‐pharmacological interventions included diet (caloric restriction or lipid enrichment), bariatric surgery and physical activity. Caloric restriction in humans achieving a mean weight loss of 3% only reduces muscle fat. Lipid‐enriched diet increases liver fat in human with no impact on muscle fat, except sphingomyelin‐enriched diet which reduces both lipid contents exclusively in pre‐clinical studies. Bariatric surgery, hybrid training (resistance exercise and electric stimulation) or whole‐body vibration in human decrease both liver and muscle fat. Physical activity impacts both phenotypes by reducing local and systemic inflammation, enhancing insulin sensitivity and modulating the expression of key mediators of the muscle‐liver‐adipose tissue axis. The combination of diet and physical activity acts synergistically in liver, muscle and white adipose tissue, and further decrease muscle and liver fat. Several pharmacological interventions (patchouli alcohol, KBP‐089, 2,4‐dinitrophenol methyl ether, adipoRon and atglistatin) and food supplementation (vitamin D or resveratrol) improve liver and muscle phenotypes in pre‐clinical studies by increasing fatty acid oxidation and anti‐inflammatory properties. These interventions are effective in reducing myosteatosis in MASLD while addressing the liver disease itself. This review supports that disturbances in inter‐organ crosstalk are key pathophysiological mechanisms involved in MASLD and myosteatosis pathogenesis. Focusing on the skeletal muscle might offer new therapeutic strategies to treat MASLD by modulating the interactions between liver and muscles.

Publisher

Wiley

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3